Use of human diploid cell MRC-5, for production of measles and rubella virus vaccines.
A further attenuated strain of measles virus, called AIK strain, developed by Makino and his colleagues at the Kitasato Institute, Tokyo, was adapted to human diploid cells (HDC), MRC-5. In a field trial it was found that this strain initiates a low rate of clinical reactions and 100% seroconversion in vaccines. An attenuated strain of rubella virus, called Takahashi strain, isolated by Shishido at the National Institute of Health, Japan, was also adapted to HDC, MRC-5. Brief details of production of an experimental rubella vaccine are given. Up to 20 harvests of virus were made from each culture without any apparent alteration of diploid cells.
D002460:Cell Line; D004171:Diploidy; D006801:Humans; D008458:Measles Vaccine; D008459:Measles virus / Q000254:growth & development; D012411:Rubella Vaccine; D012412:Rubella virus / Q000254:growth & development; D014613:Vaccines, Attenuated; D014776:Virus Cultivation / Q000379:methods*
D008458:Measles Vaccine; D012411:Rubella Vaccine; D014613:Vaccines, Attenuated